생산요소가격변화와 마크업의 변동 : 1970~1995

姜周勳,鄭郁泳,盧敬來 관동대학교 경영경제연구소 2001 경영논집 Vol.20 No.-

마크업의 결정요인은 가격과 비용의 두 가지 측면에서 고려해 볼 수 있다. 본 논문은 비용 측면에서 생산요소가격의 변화가 마크업 결정에 주요 요인임을 1970∼1995년 기간에 걸쳐 실증분석을 하였다. 대부분의 제조산업에서 마크업과 요소가격은 상호 -의 상관관계가 존재하는 것으로 실증 분석되었다. 특히 1980년대 후반부터 요소가격의 변화(실질임금 상승, 환율의 변화, 해외원자재 가격의 상승, 이자율의 변화)는 산업의 특성에 따라 전반적으로 산업별 마크업을 낮추는 결과를 가져왔다.

저공해제설제 생산의 경제적 파급효과

姜周勳,崔哲浩,盧敬來 관동대학교 경영경제연구소 2001 경영논집 Vol.20 No.-

음식물찌꺼기를 원료로 이용하여 저공해 대체 제설제를 생산하는 경우 음식물찌꺼기의 처 문제와 제설제로 인한 환경피해를 동시에 해결될 수 있다. 동시에 폐기물을 자원화하는 기회를 제공하고 기술의 발전, 수입대체효과, 수출효과 등 국민경제에 긍정적인 영향을 미칠 수 있다. 본 논문은 음식물찌꺼기를 이용하여 저공해 제설제를 생산하는 경우, 이에 대한 전반적인 경제적 효과를 분석하고 공정별 제설제 생산비용을 측정하고 그 경제성을 제시하고 있다. 음식물찌꺼기로부터 새로운 저공해 제설제를 생산하는데 소요되는 생산비용은 적정한 원료선택과 중화제의 재활용 여부등에 따라 상당히 가변적인 것으로 나타났다. 순수 chemical로 제조한 CMA의 판매가격과 비교했을 때, CaseⅡ와 CaseⅢ의 경우는 충분한 가격경쟁력을 갖출 수 있는 것으로 보인다.

Concurrent chemoradiotherapy for elderly patients with stage III non-small cell lung cancer

Kang, Ki Mun,Jeong, Bae Kwon,Ha, In Bong,Chai, Gyu Young,Lee, Gyeong Won,Kim, Hoon Gu,Kang, Jung Hoon,Lee, Won Seob,Kang, Myoung Hee The Korean Society for Radiation Oncology 2012 Radiation Oncology Journal Vol.30 No.3

Purpose: Combined chemoradiotherapy is standard management for locally advanced non-small cell lung cancer (LA-NSCLC), but standard treatment for elderly patients with LA-NSCLC has not been confirmed yet. We evaluated the feasibility and efficacy of concurrent chemoradiotherapy (CCRT) for elderly patients with LA-NSCLC. Materials and Methods: Among patients older than 65 years with LA-NSCLC, 36 patients, who underwent CCRT were retrospectively analyzed. Chemotherapy was administered 3-5 times with 4 weeks interval during radiotherapy. Thoracic radiotherapy was delivered to the primary mass and regional lymph nodes. Total dose of 54-59.4 Gy (median, 59.4 Gy) in daily 1.8 Gy fractions and 5 fractions per week. Results: Regarding the response to treatment, complete response, partial response, and no response were shown in 16.7%, 66.7%, and 13.9%, respectively. The 1- and 2-year overall survival (OS) rates were 58.2% and 31.2%, respectively, and the median survival was 15 months. The 1- and 2-year progression-free survivals (PFS) were 41.2% and 19.5%, respectively, and the median PFS was 10 months. Regarding to the toxicity developed after CCRT, pneumonitis and esophagitis with grade 3 or higher were observed in 13.9% (5 patients) and 11.1% (4 patients), respectively. Treatment-related death was not observed. Conclusion: The treatment-related toxicity as esophagitis and pneumonitis were noticeably lower when was compared with the previously reported results, and the survival rate was higher than radiotherapy alone. The results indicate that CCRT is an effective in terms of survival and treatment related toxicity for elderly patients over 65 years old with LA-NSCLC.

DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis.

Kang, Gyeong Hoon,Lee, Sun,Cho, Nam-Yun,Gandamihardja, Tasha,Long, Tiffany I,Weisenberger, Daniel J,Campan, Mihaela,Laird, Peter W United States and Canadian Academy of Pathology [e 2008 Laboratory investigation Vol.88 No.2

<P>Transcriptional silencing by CpG island hypermethylation is a potential mechanism for the inactivation of tumor-related genes. Virtually, all types of human cancers show CpG island hypermethylation, and gastric carcinoma (GC) is one of the tumors with a high frequency of aberrant CpG island hypermethylation. In this study, we prescreened DNA methylation of 170 CpG island loci in a training set of 8 paired GC and GC-associated non-neoplastic mucosae (GCN) using MethyLight technology and selected 27 DNA methylation markers showing higher methylation frequency or level in GC than in GCN. These markers were then analyzed in a tester set of 25 paired GC and GCN and 27 chronic gastritis (CG) from non-cancer patients to generate their DNA methylation profiles. We identified 17 novel methylation markers in GC, including SFRP4, SEZ6L, TWIST1, BCL2, KL, TERT, SCGB3A1, IGF2, GRIN2B, SFRP5, DLEC1, HOXA1, CYP1B1, SMAD9, MT1G, NR3C1, and HOXA10. Of the 27 selected CpG island loci, 23 were methylated in GC, GCN, and CG and the remainder four loci (DLEC1, CHFR, CYP1B1, and NR3C1) were only methylated in GC. We found that the number of methylated loci was significantly higher in GC than in GCN or CG and that Helicobacter pylori infection was strongly associated with aberrant CpG island hypermethylation in CG. Hypermethylation was more prevalent in Epstein-Barr virus (EBV)-positive GC than in EBV-negative GC and in diffuse-type GC than in intestinal-type GC. Through our large-scale screening of 170 CpG island loci, we found 17 new DNA methylation markers of GC, which may serve as useful markers that may identify a distinct subset of GC.</P>

Comparison of DNA hypermethylation patterns in different types of uterine cancer: Cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma

Kang, Sokbom,Kim, Jae Weon,Kang, Gyeong Hoon,Lee, Sun,Park, Noh Hyun,Song, Yong Sang,Park, Sang Yoon,Kang, Soon Beom,Lee, Hyo Pyo Alan R. Liss, Inc 2006 International journal of cancer Vol.118 No.9

<P>The incidence of cervical adenocarcinoma (CA) is rising, whereas the incidence of cervical squamous cell carcinoma (CSCC) continues to decrease. However, it is still unclear whether different molecular characteristics underlie these 2 types of cervical carcinoma. To better understand the epigenetic characteristics of cervical carcinoma, we investigated the DNA promoter hypermethylation profiles in CA and CSCC. In addition, we investigated whether DNA hypermethylation patterns might be used for the molecular diagnosis of CA and endometrial adenocarcinoma (EA). Using the bisulfite-modification technique and methylation-specific PCR, we examined the aberrant promoter hypermethylation patterns of 9 tumor suppressor genes (APC, DAPK, CDH1, HLTF, hMLH1, p16, RASSF1A, THBS1 and TIMP3) in 62 CSCCs, 30 CAs and 21 EAs. After Bonferroni correction adjustment (statistically significant at p < 0.0055), we found that the aberrant hypermethylations of CDH1 and DAPK were more frequent in CSCCs than in CAs (80.6% vs. 43.3%, p = 0.001; 77.4% vs. 46.7%, p = 0.005), whereas HLTF and TIMP3 were more frequently methylated in CAs (3.2% vs. 43.3%, p < 0.001; 8.1% vs. 53.3%, p = 0.001). The hypermethylations of RASSF1A and APC were more frequent in CAs than in CSCCs, but this was not significant (9.7% vs. 33.3%, p = 0.008; and 14.5% vs. 40.0%, respectively, p = 0.009). In addition, RASSF1A hypermethylation was significantly more frequent in EAs than in CAs (81.0% vs. 33.3%, p = 0.001). In conclusion, the existence of these unique methylation patterns in these cancers suggests that their tumorigenesis may involve different epigenetic mechanisms. © 2005 Wiley-Liss, Inc.</P>

Glomerular Fingerprint Deposits in Hepatitis B Virus-associated Nephropathy

Kang, Gyeong Hoon,Lee, Hyun Soon Seoul National University 1992 The seoul journal of medicine Vol.33 No.1

Human Herpesvirus 8 in Kaposi's Sarcoma and Kaposi's Sarcoma-mimicking Vascular Tumors

Gyeong Hoon Kang Korean Academy of Medical Science 1998 Journal of Korean medical science Vol.13 No.1

중합효소연쇄반응을 이요한 결핵성간염의 확진

강경훈(Gyeong Hoon Kang),김용일(Yong Il Kim),김철우(Cheol Woo Kim) 대한소화기학회 1998 대한소화기학회지 Vol.30 No.3

A 29-year-old patient developed an adverse reaction to antituberculous drugs adrninistered for tuberculous pleurisy. In spite of discontinuation of anti-tuberculous medication for 6 months, alkaline phsophatase level continuously increased and serum transaminase levels remained still high. Liver needle biopsy revealed multiple small collections of clear cells as well as nonspecific hepatitis and failed to demonstrate epithelioid granuloma or acid-fast bacilli by Ziehl-Neelsen staining. However, using the polymerase chain reaction technique, we confirmed hepatic invovement of tuberculosis based on the result of amplified Mycobacteriurn-specific DNA fragment. (Korean J Gastroenterol 1997; 30:415-419)

Concurrent chemoradiotherapy for elderly patients with stage III non-small cell lung cancer

Ki Mun Kang,Bae Kwon Jeong,In Bong Ha,Gyu Young Chai,Gyeong Won Lee,Hoon Gu Kim,Jung Hoon Kang,Won Seob Lee,Myoung Hee Kang 대한방사선종양학회 2012 Radiation Oncology Journal Vol.30 No.3

Purpose: Combined chemoradiotherapy is standard management for locally advanced non-small cell lung cancer (LA-NSCLC), but standard treatment for elderly patients with LA-NSCLC has not been confirmed yet. We evaluated the feasibility and efficacy of concurrent chemoradiotherapy (CCRT) for elderly patients with LA-NSCLC. Materials and Methods: Among patients older than 65 years with LA-NSCLC, 36 patients, who underwent CCRT were retrospectively analyzed. Chemotherapy was administered 3-5 times with 4 weeks interval during radiotherapy. Thoracic radiotherapy was delivered to the primary mass and regional lymph nodes. Total dose of 54-59.4 Gy (median, 59.4 Gy) in daily 1.8 Gy fractions and 5 fractions per week. Results: Regarding the response to treatment, complete response, partial response, and no response were shown in 16.7%, 66.7%, and 13.9%, respectively. The 1- and 2-year overall survival (OS) rates were 58.2% and 31.2%, respectively, and the median survival was 15 months. The 1- and 2-year progression-free survivals (PFS) were 41.2% and 19.5%, respectively, and the median PFS was 10 months. Regarding to the toxicity developed after CCRT, pneumonitis and esophagitis with grade 3 or higher were observed in 13.9% (5 patients) and 11.1% (4 patients), respectively. Treatment-related death was not observed. Conclusion: The treatment-related toxicity as esophagitis and pneumonitis were noticeably lower when was compared with the previously reported results, and the survival rate was higher than radiotherapy alone. The results indicate that CCRT is an effective in terms of survival and treatment related toxicity for elderly patients over 65 years old with LA-NSCLC.

IIIB 병기 비소세포폐암에서 Paclitaxel과 Cisplatin을 이용한 선행항암화학요법과 동시 항암화학방사선치료

강기문(Ki Mun Kang),이경원(Gyeong Won Lee),강정훈(Jung Hoon Kang),김훈구(Hoon Gu Kim),이원섭(Won Seob Lee),채규영(Gyu Young Chai) 대한방사선종양학회 2006 Radiation Oncology Journal Vol.24 No.4

목 적: III 병기 비소세포폐암의 치료는 항암화학요법, 수술, 방사선치료가 포함된 병용치료가 표준방법으로 알려져 있다. 본 연구에서는 IIIB 병기 비소세포폐암에서 paclitaxel과 cisplatin을 이용한 선행항암화학요법과 동시 항암화학 방사선치료를 시행하여 그 효과에 대하여 알아보고자 하였다. 대상 및 방법: 2000년 7월부터 2005년 10월까지 IIIB 병기 비소세포폐암으로 선행항암화학요법과 동시 항암화학방사선치료를 받았던 39명을 대상으로 하였다. 선행항암화학요법은 3주 간격으로 paclitaxel (175 mg/m2)과 cisplatin (75 mg/m2)을 1일째와 21일째 정맥투여하였다. 동시 항암화학요법은 43일째, 50일째, 57일째, 71일째, 78일째, 85일째 paclitaxel (60 mg/m2)과 cisplatin (25 mg/m2)을 정맥투여하였다. 흉부방사선치료는 1회 1.8 Gy씩, 주 5회 분할조사하였으며 총방사선량은 54∼59.4 Gy이었다(중앙값: 59.4 Gy). 결 과: 추적관찰기간은 6∼63개월이었으며 중앙추적관찰기간은 21개월이었다. 선행항암화학요법 후 치료반응은 부분반응 41.0% (16명), 무반응 59.0% (23명)였다. 동시 항암화학방사선치료 후 치료반응은 완전관해가 10.3% (4명),부분반응 41.0% (16명), 무반응 49.7% (19명)로 치료 반응률은 51.3%였다. 1년, 2년, 3년 생존율은 각각 66.7%,40.6%, 27.4%였으며 중앙 생존기간은 20개월이었다. 1년, 2년, 3년 무진행 생존율은 각각 43.6%, 24.6%, 24.6%였으며 중앙 무진행 생존기간은 10.7개월이었다. 동시 항암화학방사선치료 후 부작용으로 3도 이상의 식도염은 46.3%(18명), 폐렴은 28.2% (11명)에서 발생하였다. 결 론: IIIB 병기 비소세포폐암에서 paclitaxel과 cisplatin을 이용한 선행항암화학요법과 동시 항암화학방사선치료를 시행한 결과 비교적 효과적이었다. 그러나 식도염과 폐렴이 많아 부작용을 줄이기 위해 적절한 항암제의 선택 또는 방사선치료와의 병용치료의 변화가 필요할 것으로 판단되었다. Purpose: Combined modality therapy including chemotherapy, surgery and radiotherapy is considered the standard of care for the treatment of stage III non-small cell lung cancer (NSCLC). This study was conducted to evaluate the efficacy of paclitaxel and cisplatin with induction chemotherapy followed by concurrent chemoradiotherapy for stage IIIB NSCLC. Materials and Methods: Between July 2000 and October 2005, thirty-nine patients with stage IIIB NSCLC were treated with two cycles of induction chemotherapy followed by concurrent chemoradiotherapy. The induction chemotherapy included the administration of paclitaxel (175 mg/m2) by intravenous infusion on day 1 and treatment with cisplatin (75 mg/m2) by intravenous infusion on day 1 every 3 weeks. Concurrent chemoradiotherapy included the use of paclitaxel (60 mg/m2) plus cisplatin (25 mg/m2) given intravenously for 6 weeks on day 43, 50, 57, 71, 78 and 85. Thoracic radiotherapy was delivered with 1.8 Gy daily fractions to a total dose of 54∼59.4 Gy in 6∼7 weeks (median: 59.4 Gy). Results: The follow up period was 6∼63 months (median: 21 months). After the induction of chemotherapy, 41.0% (16 patients) showed a partial response and 59.0% (23 patients) had stable disease. After concurrent chemoradiotherapy, 10.3% (4 patients) had a complete response, 41.0% (16 patients) had a partial response, and the overall response rate was 51.3% (20 patients). The 1-, 2-, 3-year overall survival rates were 66.7%, 40.6%, and 27.4% respectively, with a median survival time of 20 months. The 1-, 2-, 3-year progression free survival rates were 43.6%, 24.6%, and 24.6%, respectively, with median progression free survival time of 10.7 months. Induction chemotherapy was well tolerated. Among 39 patients who completed the entire treatment including chemoradiotherapy, 46.3% (18 patients) had esophagitis greater than grade 3 and 28.2% (11 patients) had radiation pneumonitis greater than grade 3. Conclusion: Paclitaxel and cisplatin with induction chemotherapy followed by concurrent chemoradiotherapy for stage IIIB NSCLC seems to be an effective treatment. Occurrence of esophagitis and pneumonitis represents a significant morbidity and suggests a modification of the treatment regimen, either with the chemotherapy schedule or with radiotherapy treatment planning.